The rapid emergence of resistance to EGFR TKIs27,28 seems counter intuitive in the context of low-mutation burden, and the impact of intra-tumor heterogeneity on the extent of tumor shrinkage and eventual emergence of drug resistance is not well established. The gene discussed is EGFR; the disease is neoplasm.